Intravenous immunoglobulin therapy in rheumatic diseases
- 10 May 2011
- journal article
- review article
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 7 (6), 349-359
- https://doi.org/10.1038/nrrheum.2011.61
Abstract
Prepared from the collective plasma of several thousand people, therapeutic intravenous immunoglobulin (IVIg) consists mostly of human polyspecific IgG. In addition to its use in primary and secondary immune deficiencies, IVIg is used in the treatment of several rheumatic conditions, including Kawasaki disease, dermatomyositis and antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis. In these diseases, IVIg therapy generally involves the use of 2 g/kg administered over either 2 or 5 consecutive days. However, dosage regimens have not been thoroughly explored, and indications for IVIg in most rheumatic diseases, such as systemic lupus erythematosus, polymyositis and catastrophic antiphospholipid syndrome, derive from its off-label usage. Randomized clinical trials are warranted to support the evidence-based use of IVIg, and to identify the ideal administration protocols to maximize the benefits of what is a limited resource. Further research to improve the therapeutic application of IVIg relies essentially on the conception of next-generation immunoglobulin preparations and optimization of combined therapies with immunomodulatory drugs and biologic agents.Keywords
This publication has 117 references indexed in Scilit:
- The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki diseaseClinical and Experimental Immunology, 2010
- Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistanceHuman Immunology, 2010
- Basophils and the T helper 2 environment can promote the development of lupus nephritisNature Medicine, 2010
- T cells as therapeutic targets in SLENature Reviews Rheumatology, 2010
- Pathogenesis of human systemic lupus erythematosus: recent advancesTrends in Molecular Medicine, 2010
- Regulatory T cells as therapeutic targets in rheumatoid arthritisNature Reviews Rheumatology, 2009
- Identification of a receptor required for the anti-inflammatory activity of IVIGProceedings of the National Academy of Sciences, 2008
- Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG FcScience, 2008
- Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficienciesClinical and Experimental Immunology, 2008
- Resistance to Intravenous Immunoglobulin in Children with Kawasaki DiseaseThe Journal of Pediatrics, 2008